Navigation Links
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
Date:9/9/2014

LONDON, September 9, 2014 /PRNewswire/ --

On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Zoetis Inc.'s stock finished Monday's session 0.67% higher at $36.28. A total of 1.91 million shares were traded, which was below its three months average volume of 2.76 million shares. The stock vacillated between $35.95 and $36.31 during the session. Over the last one month and over the previous three months, Zoetis Inc.'s shares have gained 12.25% and 14.30%, respectively. Additionally, from the beginning of 2014, the stock has advanced 10.98%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $33.35 is greater than its 200-day moving average of $31.43. Zoetis Inc.'s stock traded at a PE ratio of 25.51 and has a Relative Strength Index (RSI) of 76.74. Sign up and read the free notes on ZTS at:

www.Investor-Edge.com/ZTS-09Sep2014

On Monday, shares in Actavis PLC fluctuated between $228.84 and $233.34 before ending the session 0.73% higher at $232.97. The stock reported a trading volume of 1.41 million shares, lower than its three months average volume of 2.29 million shares. Shares of the company traded at a PE ratio of 49.44. Actavis PLC's shares have gained 1.93% in the previous three trading sessions, 13.21% in the last one month, and 38.67% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $218.79 and $200.67, respectively. Moreover, shares of Actavis PLC have an RSI of 70.13. The complimentary notes on ACT can be downloaded as in PDF format at:

www.Investor-Edge.com/ACT-09Sep2014

Horizon Pharma Inc.'s stock rallied 7.37%, to close the day at $10.35. The stock recorded a trading volume of 1.25 million shares, below its three months average volume of 1.88 million shares. The company's shares oscillated between $9.60 and $10.47 during the session. Over the last three trading sessions and over the past one month, Horizon Pharma Inc.'s shares have advanced 2.68% and 12.13%, respectively. Further, the stock has gained an upside of 35.83% since the start of this year. The company's stock is trading below its 50-day and 200-day moving averages. Horizon Pharma Inc.'s 50-day moving average of $11.78 is above its 200-day moving average of $11.65. Additionally, the stock has an RSI of 40.98. Register for free on Investor-Edge and access the latest research on HZNP at:

www.Investor-Edge.com/HZNP-09Sep2014

On Monday, shares in Hospira Inc. recorded a trading volume of 1.65 million shares, higher than its three months average volume of 1.10 million shares. The stock ended the day at $52.72, which was 2.19% below its previous day's closing of $53.90, and registered an intraday range of $52.47 and $53.84. Shares of the company traded at a PE ratio of 28.74. Although Hospira Inc.'s stock has fallen by 2.10% in the previous three trading sessions and 3.05% in the last one month, it has gained 27.71% on YTD basis. The company's stock is trading above its 200-day moving average of $46.39, which is below the 50-day moving average of $53.09. Furthermore, shares of Hospira Inc. have an RSI of 49.88. The complete research on HSP is available for free at:

www.Investor-Edge.com/HSP-09Sep2014

Endocyte Inc.'s stock surged 4.09% to end Monday's session at $6.87. The stock recorded a trading volume of 0.76 million shares, below its three months average volume of 1.10 million shares. The company's shares fluctuated between $6.58 and $6.95 during the session. Shares of the company traded at a PE ratio of 25.44. Endocyte Inc.'s shares have lost 35.67% since the start of this year. However, the stock has advanced 0.29% over the previous three trading sessions and 2.38% in the last one month. The company's stock is trading above its 50-day moving average. Endocyte Inc.'s 200-day moving average of $11.04 is above its 50-day moving average of $6.55. Additionally, the stock has an RSI of 47.36. Free in depth research on ECYT is available at:

www.Investor-Edge.com/ECYT-09Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



'/>"/>
SOURCE Investor-Edge
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
2. Chiasma Closes $38.5 Million Equity Financing
3. Riordan Lewis & Haden
4. Equity Partners Acquires Nutritional Therapy Provider DCRX Infusion
5. Fulcrum Equity Partners Provides $5 Million in Growth Equity to Medical Direct Club
6. Guggenheim Securities Expands Healthcare Equity Research Team
7. Sentara Healthcare, MDLIVE Forge Unique Equity Partnership in Virtual Medicine
8. Ultra Clean to Present at the ThinkEquity 9th Annual Growth Conference
9. Omnicell To Present At Think Equitys 9th Annual Growth Conference: G9
10. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
11. Salveo Specialty Pharmacy, Inc. Completes Additional Equity and Debt Financings and Acquisition of Mission Road Pharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):